vs

Side-by-side financial comparison of ASCENT INDUSTRIES CO. (ACNT) and Xilio Therapeutics, Inc. (XLO). Click either name above to swap in a different company.

Xilio Therapeutics, Inc. is the larger business by last-quarter revenue ($13.7M vs $11.9M, roughly 1.2× ASCENT INDUSTRIES CO.). Xilio Therapeutics, Inc. runs the higher net margin — 75.7% vs -8.8%, a 84.5% gap on every dollar of revenue. ASCENT INDUSTRIES CO. produced more free cash flow last quarter ($-196.0K vs $-2.1M).

Ascent Capital Group, Inc. was a publicly traded holding company whose primary subsidiary was Monitronics. Ascent Media was a wholly owned subsidiary of the Discovery Holding Company (DHC). DHC spun off Ascent Media as an independent, public company on September 17, 2008.

Xilio Therapeutics is a clinical-stage biotechnology company dedicated to developing novel tumor-selective immunotherapies for cancer treatment. Its product pipeline features candidates engineered to trigger anti-tumor immune responses specifically inside tumor microenvironments, reducing systemic toxicities, and it primarily targets oncology patient populations in North America and other global markets.

ACNT vs XLO — Head-to-Head

Bigger by revenue
XLO
XLO
1.2× larger
XLO
$13.7M
$11.9M
ACNT
Higher net margin
XLO
XLO
84.5% more per $
XLO
75.7%
-8.8%
ACNT
More free cash flow
ACNT
ACNT
$1.9M more FCF
ACNT
$-196.0K
$-2.1M
XLO

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ACNT
ACNT
XLO
XLO
Revenue
$11.9M
$13.7M
Net Profit
$-1.0M
$10.4M
Gross Margin
14.6%
Operating Margin
-21.0%
-86.5%
Net Margin
-8.8%
75.7%
Revenue YoY
13.3%
Net Profit YoY
-1.2%
179.1%
EPS (diluted)
$-0.11
$-3.74

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ACNT
ACNT
XLO
XLO
Q4 25
$11.9M
$13.7M
Q3 25
$19.7M
$19.1M
Q2 25
$18.7M
$8.1M
Q1 25
$24.7M
$2.9M
Q4 24
$10.5M
Q3 24
$20.9M
Q2 24
$21.5M
Q1 24
$28.0M
Net Profit
ACNT
ACNT
XLO
XLO
Q4 25
$-1.0M
$10.4M
Q3 25
$-2.1M
$-16.3M
Q2 25
$6.3M
$-15.8M
Q1 25
$-2.3M
$-13.3M
Q4 24
$-1.0M
Q3 24
$-6.2M
Q2 24
$-926.0K
Q1 24
$-5.5M
Gross Margin
ACNT
ACNT
XLO
XLO
Q4 25
14.6%
Q3 25
29.7%
Q2 25
26.1%
Q1 25
19.3%
Q4 24
24.3%
Q3 24
14.4%
Q2 24
13.1%
Q1 24
8.3%
Operating Margin
ACNT
ACNT
XLO
XLO
Q4 25
-21.0%
-86.5%
Q3 25
-4.1%
-10.1%
Q2 25
-14.4%
-177.7%
Q1 25
-4.2%
-472.7%
Q4 24
-25.4%
Q3 24
-9.4%
Q2 24
-8.6%
Q1 24
-15.5%
Net Margin
ACNT
ACNT
XLO
XLO
Q4 25
-8.8%
75.7%
Q3 25
-10.6%
-85.4%
Q2 25
33.7%
-196.0%
Q1 25
-9.3%
-452.7%
Q4 24
-9.8%
Q3 24
-29.5%
Q2 24
-4.3%
Q1 24
-19.7%
EPS (diluted)
ACNT
ACNT
XLO
XLO
Q4 25
$-0.11
$-3.74
Q3 25
$-0.22
$-0.11
Q2 25
$0.65
$-0.16
Q1 25
$-0.23
$-0.18
Q4 24
$-0.11
Q3 24
$-0.61
Q2 24
$-0.09
Q1 24
$-0.54

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ACNT
ACNT
XLO
XLO
Cash + ST InvestmentsLiquidity on hand
$57.6M
$137.5M
Total DebtLower is stronger
Stockholders' EquityBook value
$87.0M
$35.3M
Total Assets
$111.9M
$154.7M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ACNT
ACNT
XLO
XLO
Q4 25
$57.6M
$137.5M
Q3 25
$58.0M
$103.8M
Q2 25
$60.5M
$121.6M
Q1 25
$14.3M
$89.1M
Q4 24
$16.1M
Q3 24
$8.5M
Q2 24
$3.6M
Q1 24
$1.3M
Total Debt
ACNT
ACNT
XLO
XLO
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
$0
Q3 24
Q2 24
Q1 24
Stockholders' Equity
ACNT
ACNT
XLO
XLO
Q4 25
$87.0M
$35.3M
Q3 25
$87.1M
$-8.1M
Q2 25
$89.7M
$7.1M
Q1 25
$91.2M
$10.7M
Q4 24
$93.5M
Q3 24
$94.7M
Q2 24
$101.0M
Q1 24
$102.0M
Total Assets
ACNT
ACNT
XLO
XLO
Q4 25
$111.9M
$154.7M
Q3 25
$119.9M
$133.7M
Q2 25
$122.6M
$133.8M
Q1 25
$152.5M
$103.7M
Q4 24
$147.3M
Q3 24
$148.6M
Q2 24
$158.2M
Q1 24
$161.0M
Debt / Equity
ACNT
ACNT
XLO
XLO
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
0.00×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ACNT
ACNT
XLO
XLO
Operating Cash FlowLast quarter
$266.0K
$-2.0M
Free Cash FlowOCF − Capex
$-196.0K
$-2.1M
FCF MarginFCF / Revenue
-1.7%
-15.3%
Capex IntensityCapex / Revenue
3.9%
0.7%
Cash ConversionOCF / Net Profit
-0.19×
TTM Free Cash FlowTrailing 4 quarters
$-2.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ACNT
ACNT
XLO
XLO
Q4 25
$266.0K
$-2.0M
Q3 25
$1.3M
$-17.5M
Q2 25
$-1.4M
$-14.5M
Q1 25
$-700.0K
$29.0M
Q4 24
$8.8M
Q3 24
$3.4M
Q2 24
$2.2M
Q1 24
$263.0K
Free Cash Flow
ACNT
ACNT
XLO
XLO
Q4 25
$-196.0K
$-2.1M
Q3 25
$695.0K
Q2 25
$-1.5M
$-14.9M
Q1 25
$-1.0M
$29.0M
Q4 24
$8.4M
Q3 24
$3.1M
Q2 24
$1.9M
Q1 24
$25.0K
FCF Margin
ACNT
ACNT
XLO
XLO
Q4 25
-1.7%
-15.3%
Q3 25
3.5%
Q2 25
-8.3%
-184.0%
Q1 25
-4.1%
988.3%
Q4 24
80.6%
Q3 24
15.1%
Q2 24
9.1%
Q1 24
0.1%
Capex Intensity
ACNT
ACNT
XLO
XLO
Q4 25
3.9%
0.7%
Q3 25
3.1%
0.0%
Q2 25
0.8%
5.0%
Q1 25
1.3%
0.8%
Q4 24
3.7%
Q3 24
1.3%
Q2 24
1.0%
Q1 24
0.9%
Cash Conversion
ACNT
ACNT
XLO
XLO
Q4 25
-0.19×
Q3 25
Q2 25
-0.22×
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ACNT
ACNT

Other$6.1M52%
Transferred At Point In Time$5.7M48%

XLO
XLO

Segment breakdown not available.

Related Comparisons